Sorafenib-d3

• CAT Number: R006046
• CAS Number: 1130115-44-4
• Molecular Formula: C21H16ClF3N4O3
• Molecular Weight: 467.848
• Purity: ≥95%
• Target: multikinase inhibitor
• Storage: -20°C
• IUPAC Name: 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-(trideuteriomethyl)pyridine-2-carboxamide
• InChI: InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)/i1D3
• InChIKey: MLDQJTXFUGDVEO-FIBGUPNXSA-N
• SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F

Donafenib, also known as CM-4307, is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC).

Reference

1: Ho V, Lim TS, Lee J, Steinberg J, Szmyd R, Tham M, Yaligar J, Kaldis P, Abastado JP, Chew V. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. Oncotarget. 2015 Jul 23. [Epub ahead of print] PubMed PMID: 26287667.2: Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer. 2014 Oct;3(3-4):405-16. doi: 10.1159/000343861. Review. PubMed PMID: 26280002; PubMed Central PMCID: PMC4531424.3: Kudo M. Biomarkers and Personalized Sorafenib Therapy. Liver Cancer. 2014 Oct;3(3-4):399-404. doi: 10.1159/000343870. PubMed PMID: 26280001; PubMed Central PMCID: PMC4531426.4: Erika G, Federica Z, Martina S, Anselmo P, Luigi R, Marina M, Davide C, Eleonora Z, Monica V, Silverio T. Old tyrosine kinase inhibitors and newcomers in gastrointestinal cancer treatment. Curr Cancer Drug Targets. 2015 Aug 17. [Epub ahead of print] PubMed PMID: 26278713.5: Liu JY, Chiang T, Liu CH, Chern GG, Lin TT, Gao DY, Chen Y. Delivery of siRNA using CXCR4-Targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Anti-Tumor Response in Liver Cancer. Mol Ther. 2015 Aug 17. doi: 10.1038/mt.2015.147. [Epub ahead of print] PubMed PMID: 26278330.6: Huang J, Yan L, Wu H, Yang J, Liao M, Zeng Y. Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation? J Surg Res. 2015 Jul 28. pii: S0022-4804(15)00807-0. doi: 10.1016/j.jss.2015.07.033. [Epub ahead of print] PubMed PMID: 26277218.7: Janjigian YY, Vakiani E, Ku GY, Herrera JM, Tang LH, Bouvier N, Viale A, Socci ND, Capanu M, Berger M, Ilson DH. Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PLoS One. 2015 Aug 14;10(8):e0134731. doi: 10.1371/journal.pone.0134731. eCollection 2015. PubMed PMID: 26275293.8: Jiang E, Shangguan AJ, Chen S, Tang L, Zhao S, Yu Z. The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma. Cancer Lett. 2015 Aug 10. pii: S0304-3835(15)00471-1. doi: 10.1016/j.canlet.2015.07.016. [Epub ahead of print] PubMed PMID: 26272181.9: Sacco R, Antonucci M, Bargellini I, Marceglia S, Mismas V, Cabibbo G. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice? Future Oncol. 2015 Aug 13:1-3. [Epub ahead of print] PubMed PMID: 26270206.10: Ch/’ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol. 2015 Aug 8;7(16):2029-40. doi: 10.4254/wjh.v7.i16.2029. Review. PubMed PMID: 26261692; PubMed Central PMCID: PMC4528276.